Delisting risk
Scienture (SCNX)
Specialty drug developer commercializing differentiated formulations for cardiovascular and CNS care.
$0.3810
Pre-market+0.01 (+2.97%)
At close$0.3700(+0.54%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Cost of revenue | 0 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross profit | 0 | −2 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| 1 | 4 | 5 | 1 | 4 | 4 | 4 | 5 | 5 | 3 | 3 | 3 | |
| Research & development | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 |
| 1 | 4 | 5 | 1 | 2 | 3 | 3 | 4 | 5 | 3 | 2,007 | 2 | |
| Selling & marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & administrative | 1 | 4 | 5 | 1 | 2 | 3 | 3 | 4 | 5 | 3 | 2,007 | 2 |
| Other expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −2,005 | 0 |
| Operating income | −1 | −6 | −5 | −1 | −3 | −4 | −4 | −5 | −4 | −3 | −4 | −3 |
| 1 | −6 | −1 | 0 | 0 | −3 | 1 | −2 | 1 | −27 | 0 | 0 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest expense | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 1 | 0 | 0 |
| Other non-operating income | −1 | 5 | 1 | 0 | −1 | 2 | −1 | 1 | −3 | 26 | 0 | 0 |
| Income before tax | 0 | −12 | −7 | −2 | −3 | −7 | −3 | −7 | −4 | −30 | −3 | −3 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | −1 | 0 | 0 | 0 | −2 | 0 | 0 |
| Net income from continuing operations | 0 | −12 | −7 | −2 | −3 | −7 | −3 | −7 | −4 | −28 | −3 | −3 |
| Discontinued operations | −3 | 0 | −2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | −4 | −12 | −8 | −2 | −3 | −7 | −3 | −7 | −4 | −28 | −3 | −3 |
| EPS, basic | −$4.57 | −$13.01 | −$8.14 | −$1.30 | −$1.34 | −$0.82 | −$0.33 | −$0.48 | −$0.19 | −$1.51 | −$0.08 | −$0.07 |
| EPS, diluted | −$1.49 | −$4.93 | −$6.66 | −$0.77 | −$1.34 | −$0.82 | −$0.33 | −$0.48 | −$0.19 | −$1.70 | −$0.08 | −$0.07 |
| Weighted average shares, basic | 1 | 1 | 1 | 1 | 2 | 9 | 9 | 14 | 19 | 153 | 406 | 40 |
| Weighted average shares, diluted | 2 | 2 | 1 | 2 | 2 | 9 | 9 | 14 | 19 | 153 | 406 | 40 |
| EBITDA | 0 | −10 | −7 | −2 | −3 | −6 | −2 | −6 | −2 | −29 | −3 | −3 |
| Depreciation & amortization | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | 0 | −11 | −7 | −2 | −3 | −6 | −2 | −6 | −2 | −29 | −3 | −3 |